Enzo Biochem, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 89   

Articles published

ENZ 2.89 -0.03 (-1.03%)
price chart
Enzo Biochem, Inc. Analyst Rating Update
Enzo Biochem, Inc. (NYSE:ENZ) shares are expected to touch $7 in the short term. This short term price target has been shared by 1 analysts.
Enzo Biochem, Inc. (NYSE:ENZ) Short Interest Update
Enzo Biochem, Inc. (NYSE:ENZ) ensharesed a drop of 63.1% or -1,336,899 shares in the short positions. The number dropped from 2,117,474 on June 30,2015 to 780,575 on July 15,2015.
Shares of Enzo Biochem, Inc. (NYSE:ENZ) Drops by -3.33%
Enzo Biochem, Inc. (NYSE:ENZ) has lost 3.33% during the past week and dropped 3.33% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 2.11%.
Company Shares of Enzo Biochem, Inc. Drops by -3.23%
Enzo Biochem, Inc. (NYSE:ENZ) has dropped 3.23% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 3.09% in the last 4 weeks.
Latest Report – Global Enzo Biochem, Inc. – Product Pipeline Market Review ...
Global Markets Direct's, 'Enzo Biochem, Inc. - Product Pipeline Review - 2014′, provides an overview of the Enzo Biochem, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic ...
Enzo Biochem Reaches Patent Infringement Settlement
NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has reached and finalized a settlement with one defendant in an infringement action brought by Enzo regarding its U.S.
Enzo, Siemens Resolve IP Infringement Case  GenomeWeb
Enzo Biochem Announces New York State Approval of First FlowScript™ Assay for ...
NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) today announced that the New York State Department of Health has granted conditional approval for Enzo Clinical Labs' use of the FlowScript™ assay in detection of mRNA from HPV ...
Enzo Biochem's (ENZ) CEO Barry Weiner on Q2 2015 Results -- Earnings ...  Seeking Alpha (registration)
Enzo Biochem Announces Appointment of James M. O'Brien as Senior VP, Finance
Jim has held leadership positions in the areas of planning and strategic development, financial analysis, SEC reporting and internal controls for both large and small multi-national public companies,” said Barry Weiner, President of Enzo Biochem, Inc ...
Healthcare Stocks Little Changed; Enzo Biochem, Innate Pharma Partnering on ...  NASDAQ
Related articles »  
Enzo Biochem to Present at Cantor Fitzgerald Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ), a pioneer in molecular diagnostics, announced today that Barry Weiner, President, will be presenting at the Cantor Fitzgerald Inaugural Healthcare Conference, on Wednesday, July 8, 2015, ...
Enzo Biochem, Inc. v. Applera Corp. (Fed. Cir. 2010)
Enzo The '824, '767, '928, and '830 patents, which are owned by Plaintiffs-Appellants Enzo Biochem, Inc., Enzo Life Sciences, Inc., and Yale University ("Enzo"), are directed to various techniques for labeling and detecting nucleic acids. More ...